{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:43:34Z","timestamp":1760147014335},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T00:00:00Z","timestamp":1353456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vox Sanguinis"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p><jats:bold>Background and Objectives\u2002<\/jats:bold> The outbreak of vCJD in the UK leads to concern regarding the potential for human\u2010to\u2010human transmission of this agent. Plasma\u2010derived products such as albumin, immunoglobulin and coagulation factors were manufactured by BPL from UK plasma up until 1999 when a switch to US plasma was made. In the current study, the capacity of various manufacturing processes that were in use both prior to and after this time to remove the TSE agent was tested.<\/jats:p><jats:p><jats:bold>Materials and Methods\u2002<\/jats:bold> Small\u2010scale models of the various product manufacturing steps were developed. Intermediates were spiked with scrapie brain extract and then further processed. Samples were assayed for the abnormal form of prion protein (PrP<jats:sup>SC<\/jats:sup>) by Western blotting, and the reduction in the amount of scrapie agent determined.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Many of the manufacturing process steps produced significant reduction in the scrapie agent. Particularly effective were steps such as ethanol fractionation, depth filtration, ion\u2010exchange and copper chelate affinity chromatography. Virus retentive filters, of nominal pore size 15 or 20\u2003nm, removed &gt;3 log. The total cumulative reduction capacity for individual products was estimated to range from 7 to 14 log. In the case of factor VIII (8Y), the total removal was limited to 3 log.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> All the processes showed a substantial capacity to remove the TSE agent. However, this was more limited for the intermediate purity factor VIII 8Y which included fewer manufacturing steps.<\/jats:p>","DOI":"10.1111\/vox.12004","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T22:58:15Z","timestamp":1353538695000},"page":"299-308","source":"Crossref","is-referenced-by-count":14,"title":["Removal of TSE agent from plasma products manufactured in the United Kingdom"],"prefix":"10.1111","volume":"104","author":[{"given":"P. L.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Ternouth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Thirunavukkarasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bulmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"McLeod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,11,21]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"55","article-title":"Molecular biology of prions causing infectious and genetic encephalopathies of humans as well as scrapie of sheep and BSE of cattle","volume":"75","author":"Prusiner SB","year":"1991","journal-title":"Develop Biol Stand"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/66.1.1"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0701.010102"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0268-960X(98)90007-8"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2009.01205.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00833.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02181.x"},{"key":"e_1_2_6_9_2","unstructured":"BennettP BallJ:vCJD risk assessment calculations for a patient with multiple routes of exposure. London UK Department of Health 2009"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1741-6892.2004.00444.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2006.11.001"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9975(71)90100-9"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2007.04.005"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/85.6.887"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.1999.7740204.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04247.x"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1989.tb01144.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02414.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199412000-00010"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1962.tb03274.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-0934(99)00135-4"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2009.09.004"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.12.3688-3693.1987"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2767"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1580"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17143-2"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1442"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077054"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1042\/BA20060249"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000206"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3148.1999.009001003.x"},{"key":"e_1_2_6_32_2","first-page":"32","article-title":"Creutzfeldt\u2010Jakob disease: reflections on the risk from blood product therapy","volume":"5","author":"Brown P","year":"2007","journal-title":"Haemophilia"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2002.0327"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2007.04.008"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2006.00829.x"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2009.02067.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2003.08.004"},{"key":"e_1_2_6_38_2","unstructured":"Committee for Medicinal Products For Human Use (CHMP).European Medicines Agency: guideline on the investigation of manufacturing processes for plasma\u2010derived medicinal products with regard to vCJD risk. CPMP\/BWP\/CPMP\/5136\/03 2004."},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2001.41040449.x"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2000.7820086.x"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1423-0410.2003.00312.x"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1006\/biol.2001.0269"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2002.00160.x"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2005.11.007"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01441.x"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20071477"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2009.10.018"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2005.08.005"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.3109\/07853890009002026"},{"key":"e_1_2_6_50_2","unstructured":"Det Norske Veritas:Risk assessment of exposure to vCJD infectivity in blood and blood products: report for the Department of Health London UK. Feb 2003"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2011.02508.x"},{"key":"e_1_2_6_52_2","unstructured":"Center for Biologics Evaluation and Research US Food and Drug Administration:A 2010 update of the draft quantitative risk assessment of vCJD risk potentially associated with the use of human plasma\u2010derived factor VIII manufactured under United States (US) license from plasma collected in the US. Silver Spring MD USA Oct 2010."}],"container-title":["Vox Sanguinis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fvox.12004","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vox.12004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T19:28:54Z","timestamp":1698521334000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vox.12004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,21]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.1111\/vox.12004"],"URL":"https:\/\/doi.org\/10.1111\/vox.12004","archive":["Portico"],"relation":{},"ISSN":["0042-9007","1423-0410"],"issn-type":[{"value":"0042-9007","type":"print"},{"value":"1423-0410","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,21]]}}}